Cytori Cell Research Institute
Basic Information
- Stock Code
- 3750
- Industry
- Information and Communications
- Category Detail
- Investment
- Prefecture
- Tokyo
- Establishment Year
- October 2004
- Listing Year
- October 2004
- Official Website
- https://cytori.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Ichigo, AD Works Group, Curial, Chinushi, First Brothers, Roadstar Capital, Kasumigaseki Capital, Wealth Management, ODK, Data App, Sonocom, Fintech Global, Tosei
Overview
Cytori Cell Research Institute is a Tokyo-based investment reorganization company in the information and communications industry, established in 2004, aiming for growth with two main pillars: development of cell therapy-related equipment and real estate investment.
Current Situation
Cytori Cell Research Institute recorded consolidated sales of approximately ¥2.1 billion in the fiscal year ended March 2023, but operating and net profits were in the red, and it is in the process of business reorganization. While focusing on development and research of cell therapy-related equipment, it is concentrating on diversifying revenue through investment businesses such as real estate fund operations. It oversees related subsidiaries, expands into media and financial solutions areas, and is strengthening its management foundation. Headquartered in Tokyo with capital of ¥100 million and 64 consolidated employees, it is small-scale but excels in expertise. It is promoting management reforms for sustainable growth in response to changes in the business environment, and new revenue opportunities are expected from both medical equipment development and real estate investment. In recent years, it has withdrawn from debt management and collection business, focusing on business concentration and efficiency, with financial soundness being key going forward. It is in a strategic transition period, envisioning growth through both technological research and investment fund operations.
Trivia
Interesting Facts
- Traces its lineage to Ishii Tool Manufacturing Co., Ltd., founded in 1931, an old established company.
- Has undergone multiple name changes, adopting its current name in 2004.
- Unique corporate structure with two distinct main businesses: investment and medical equipment.
- Main investment funds specialize in Japanese income-generating real estate.
- Strategic investment business partnership as major shareholder contributes to management stability.
- Cell therapy-related medical equipment is being adopted by medical institutions domestically and internationally.
- 64 consolidated employees, small-scale but high expertise.
- Recorded ordinary deficit in FYE March 2023, working on earnings improvement.
- Includes hotel operation companies among related firms, pursuing business diversification.
- Leveraging the advantage of headquarters location in Kasumigaseki, Chiyoda-ku, Tokyo.
Hidden Connections
- Promotes technology accumulation in cell therapy field through partnerships with major medical equipment manufacturers and pharmaceutical companies.
- Secures funding and management stability through investment by Aqua Strategic Investment Business Limited Liability Partnership.
- Local governments sometimes involved indirectly as customers in investment fund business.
- Advancing collaboration with hotel operations and media businesses through related subsidiaries.
- Providing technology to cutting-edge research institutions domestically and internationally in cell therapy equipment development.
- In-house fusion of medical and investment experts building a unique business model.
- Recognized as a Tokyo Stock Exchange Standard market listed company.
- Unique management approach combining cell therapy and real estate investment across different industries.
Future Outlook
Growth Drivers
- Increased demand for medical equipment from expansion of regenerative medicine market
- Recovery in income-generating real estate market and operational efficiency improvements
- Continuous investment in new technology development and commercialization
- Enhanced corporate value through governance strengthening
- Synergy effects in medical and investment fields
- Advancement of overseas market development and international partnerships
- Strengthened business operations emphasizing sustainability
- Business efficiency improvements through management system renewal
- Diversification and expansion of investment funds
- Talent development and retention
Strategic Goals
- Achieve consolidated sales over ¥5 billion and turnaround to profitability
- Expand market share of cell therapy devices domestically and internationally
- Double the asset size of real estate funds
- Achieve ESG standard compliance and certifications across all business areas
- Create new businesses through technology development
- Strengthen balance between medical equipment and investment businesses
- Build sustainable and stable management foundation
- Further proactive contributions to local communities
- Strengthen global expansion through overseas market entry
- Maximize operational efficiency through digitalization
Business Segments
Cell Therapy Equipment Provision
- Overview
- Provides cell therapy-related equipment and services to medical institutions and research organizations.
- Competitiveness
- Advanced cell separation technology and research and development capabilities
- Customers
-
- Hospitals and clinics
- Regenerative medicine research institutions
- Pharmaceutical companies
- University-affiliated research institutes
- Biotechnology companies
- Medical equipment distributors
- Government research institutions
- International medical institutions
- Regenerative medicine startups
- Clinical trial institutions
- Products
-
- Adipose-derived cell separation system
- Cell culture consumables
- Cell analysis devices
- Therapeutic equipment software
- Clinical cell preparation devices
- Cell cryopreservation devices
- Biosensors
- Cell transport containers
- Treatment protocol management tools
- Equipment maintenance services
Real Estate Investment and Fund Operations
- Overview
- Forms and manages income-generating real estate and funds to provide returns to investors.
- Competitiveness
- Integrated management capabilities for investment and operations
- Customers
-
- Individual investors
- Corporate investors
- Pension funds
- Insurance companies
- Trust banks
- Fund managers
- Corporate pensions
- Real estate-related companies
- Real estate management companies
- Local governments
- Products
-
- Real estate investment funds
- Income-generating real estate sales
- Asset management services
- Hotel management operations
- Real estate appraisal services
- Rental management systems
- Real estate consulting
- Investment operation reports
- Environmental and energy-saving support
- Real estate transaction brokerage
Related Subsidiary Management
- Overview
- Supports comprehensive management and financial management of group companies.
- Competitiveness
- Specialized financial operations and governance structure
- Customers
-
- Group companies
- Investors
- Financial institutions
- Products
-
- Management systems
- Accounting and financial reporting
- Risk management
- Strategic planning support
- Fund management services
Competitive Advantage
Strengths
- Medical device development expertise specialized in cell therapy
- Expertise in income-generating real estate operations and fund formation
- Diversified business expansion through specialized subsidiaries
- Management base located in central Tokyo
- Secured diverse investor network
- Possession of specialized personnel in medical and investment fields
- Adaptability from long-term business reorganization experience
- Stable capital and total assets scale
- Reliability as a listed company
- Commitment to continuous research and development
- Robust collaboration system with related companies
- Presence of strategic investors in shareholder composition
- Transparency through diverse news exposure
- Technological uniqueness in medical equipment field
- Flexible organizational reorganization capabilities
Competitive Advantages
- Differentiation through specialized technology in cell therapy medical devices
- Integrated service provision for fund formation and operations
- Efficiency in business division management utilizing specialized subsidiaries
- Excellent access from location in Chiyoda-ku, Tokyo
- Major shareholder participation by Aqua Strategic Investment Business Limited Liability Partnership
- Growth strategy leveraging expertise in both medical and investment fields
- Diverse sales channels and close ties with research institutions
- Rapid response to changing market environments
- Key partner for advanced cell therapy technology
- Differentiation from competitors across multiple fields and strengthened expertise
- Optimal resource allocation through subsidiary reorganization
- Broad network of related companies and customers
- Management team's reform drive and business reconstruction experience
- Balance of advanced R&D and commercialization
- Clear governance and information disclosure stance
Threats
- Risk of intensified regulations in the medical equipment market
- Increased market competition due to rising competitors in cell therapy technology
- Impact of economic fluctuations on investment real estate market
- Pressure on financial base from ongoing losses
- Possibility that technology development results do not lead to commercialization
- Risk of demand fluctuations at medical institutions due to new infectious diseases, etc.
- Funding difficulties due to changes in investor judgment
- Decline in competitiveness due to talent outflow and recruitment challenges
- Barriers to overseas market entry and international competition
- Difficulties in risk response accompanying structural changes in related businesses
- Integration risks during business reorganization
- Delays in responding to rapid changes in market needs
Innovations
2023: Development of New Cell Therapy Medical Devices
- Overview
- Developed an advanced version of adipose-derived stem cell extraction device to expand clinical applications.
- Impact
- Achieved improved treatment outcomes and increased adoption in medical settings.
2022: Strengthening Real Estate Fund Formation
- Overview
- Revamped the fund formation structure for income-generating real estate to optimize investor returns.
- Impact
- Contributed to improved asset management efficiency and expanded investor base.
2021: Business Concentration through Management Reorganization
- Overview
- Focused operations on medical equipment and real estate, organizing non-core divisions.
- Impact
- Achieved improved earnings structure and optimal allocation of management resources.
2020: Introduction of IT Systems for Group Integrated Management
- Overview
- Built IT infrastructure for management support to improve collaboration efficiency among subsidiaries.
- Impact
- Succeeded in accelerating group-wide decision-making.
Sustainability
- Promotion of energy-saving operations in real estate to reduce environmental impact
- Practice of resource efficiency in medical equipment development
- Activation of CSR activities through strengthened community collaboration
- Active incorporation of ESG factors into investment decisions
- Improvement of sustainable growth and management transparency